Pan-European growth investor Keensight Capital has agreed to acquire a majority stake in Symeres, a provider of drug discovery and medicinal chemistry services, from Gilde Healthcare Partners.
Laboratory and imaging diagnostics service is valued at more than EUR 5bn
IK expanded its UK operations to include a local small-cap team headed by partner Tom Salmon in 2020
Asset manager nets a 10.7% IRR on the investment in its listed peer
Romanian cybersecurity company appoints JP Morgan and Morgan Stanley for a dual-track process